Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.

Clin Gastroenterol Hepatol · 2022 · PMC8026779 · PMID 33039584

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Patients treated with vedolizumab were more likely to achieve deep remission than those treated with TNF antagonist therapy (HR, 1.653; 95% CI, 0.978–2.794; P = .06); however, this did not reach statistical significance using IPW ATE.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.